Mediwhale Secures $13M Series C Funding Led by Premier Partners

Why It Matters

Securing U.S. regulatory approval positions Mediwhale to tap the $50 billion cardiovascular diagnostics market, while a KOSDAQ debut could accelerate capital inflows for Korean med‑tech innovators.

Key Takeaways

• Series C raised 20 billion won ($13 million)
• Total funding now $34 million across three rounds
• Dr Noon CVD matches cardiac CT accuracy
• Preparing FDA De Novo clearance and KOSDAQ listing

Pulse Analysis

Retinal imaging AI is reshaping preventive cardiology by turning a routine eye exam into a window on systemic health. By extracting vascular biomarkers from the retina, algorithms can flag early signs of cardiovascular disease and chronic kidney impairment, offering clinicians a non‑invasive, low‑cost screening tool. This approach aligns with a broader shift toward data‑driven diagnostics that reduce reliance on expensive imaging modalities and enable earlier intervention, a trend that investors and health systems worldwide are closely monitoring.

Mediwhale’s latest financing round underscores the commercial viability of this niche. With $13 million injected to expand clinical validation, the firm is targeting the U.S. Food and Drug Administration’s De Novo pathway—a route designed for novel, high‑impact devices lacking a predicate. Achieving clearance would not only unlock the lucrative American market but also serve as a regulatory benchmark for other jurisdictions. Simultaneously, the company’s plan to list on KOSDAQ via a technology‑focused special listing reflects confidence in sustained investor appetite for AI‑enabled health solutions.

The Korean med‑tech ecosystem is riding a wave of capital, as evidenced by recent fundraises at peers like Vuno and AITRICS. This cluster advantage fuels talent sharing, joint research, and a competitive push toward global standards. For multinational healthcare providers, the emergence of validated, retina‑based AI tools offers a scalable option to augment traditional screening programs, potentially lowering costs and improving outcomes across diverse patient populations.

Deal Summary

South Korean medical AI startup Mediwhale raised 20 billion won ($13 million) in a Series C round led by Premier Partners, with participation from KB Investment, Quad Asset Management, IMM Investment, Hana Ventures, AON Investment and Startup Partners. The capital will fund clinical trials, regulatory approvals and preparations for a KOSDAQ technology special listing in early 2027.